Valuation: Moderna, Inc.

Market Cap 24.53B 21.5B 19.87B 18.28B 34.53B 2,365B 35.08B 237B 93.02B 1,157B 92.11B 90.09B 3,985B P/E 2026 *
-7.14x
P/E 2027 * -13x
Enterprise Value 21.12B 18.51B 17.11B 15.74B 29.74B 2,037B 30.21B 204B 80.1B 996B 79.32B 77.58B 3,432B EV / Sales 2026 *
10.1x
EV / Sales 2027 * 8.81x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Moderna, Inc.

1 day-0.01%
1 week-12.86%
Current month-15.05%
1 month-6.99%
3 months+10.74%
6 months+42.22%
Current year+101.73%
1 week 59.3
Extreme 59.3
68.49
1 month 57.5
Extreme 57.5
85.6
Current year 29.81
Extreme 29.81
85.6
1 year 22.28
Extreme 22.28
85.6
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 28/02/2011
Director of Finance/CFO 49 05/09/2022
President 50 31/10/2024
Director TitleAgeSince
Chairman 63 31/01/2012
Director/Board Member 54 28/02/2011
Director/Board Member 69 10/12/2019
Date Insider Type Main position Quantity % Market Cap.
15/07/26 Fiscal year

Chairperson

160,008 0.0403%
08/07/26 Free

Director

14,766 0.0037%
05/07/26 Free

Executive/Senior Manager

57,022 0.0144%
Change 5-day change 1-year change 3-year change Capi.($)
-3.77%-12.86%+90.31%-52.47% 24.53B
-0.67%+1.15%+23.89%-6.52% 68.85B
-0.54%+0.38%+36.12%+192.81% 52.13B
-3.65%+34.50%+34.50%+34.50% 43.46B
-0.58%-0.23%-52.36%-53.82% 41.24B
-2.93%+0.40%+59.97%-27.79% 30.41B
-1.36%-0.91%+70.42%+83.86% 23.42B
+3.99%+3.12%+3.87%+200.81% 19.75B
+0.26%-1.74%+70.47%+125.19% 16.57B
-0.76%-5.97%+73.64%+134.36% 15.95B
Average -0.62%-1.45%+41.08%+63.09% 33.63B
Weighted average by Cap. -0.91%-0.69%+32.63%+50.25%

Financials

2026 *2027 *
Net sales 2.1B 1.84B 1.7B 1.56B 2.95B 202B 3B 20.26B 7.94B 98.83B 7.87B 7.69B 340B 2.55B 2.24B 2.07B 1.9B 3.59B 246B 3.65B 24.67B 9.68B 120B 9.58B 9.37B 415B
Net income -3.41B -2.99B -2.76B -2.54B -4.8B -329B -4.88B -32.97B -12.93B -161B -12.8B -12.52B -554B -1.85B -1.62B -1.5B -1.38B -2.6B -178B -2.64B -17.88B -7.01B -87.23B -6.94B -6.79B -300B
Net Debt -3.41B -2.99B -2.76B -2.54B -4.8B -328B -4.87B -32.94B -12.92B -161B -12.79B -12.51B -553B -2.05B -1.8B -1.66B -1.53B -2.89B -198B -2.94B -19.85B -7.79B -96.85B -7.71B -7.54B -334B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
20/07/26 US$59.49 -3.77% 4,941,040
17/07/26 US$61.82 -2.11% 4,551,991
16/07/26 US$63.15 -7.51% 5,593,100
15/07/26 US$68.28 +1.25% 3,427,825
14/07/26 US$67.44 +0.64% 5,812,332
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
61.82USD
Average target price
49.37USD
Spread / Average Target
-20.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock